Harrow Closes Acquisition of TYRVAYA®

{
  "signal_id": "f90be767-e414-0c98-5bd6-fbe9a0aec51a",
  "signal_type": "news",
  "signal_subtype": "sells_assets_to",
  "detected_at": "2026-10-05T11:00:00+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/05/3374393/0/en/harrow-closes-acquisition-of-tyrvaya.html",
    "title": "Harrow Closes Acquisition of TYRVAYA®",
    "assets": "worldwide rights to TYRVAYA, except for Japan",
    "excerpt": "NASHVILLE, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA ® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. At closing, Harrow acquired worldwide rights to TYRVAYA, except for Japan. Viatris retained the rights to commercialize TYRVAYA in Japan and agreed to pay Harrow royalties on any future net sales there. Consistent with the terms announced in August, Harrow paid $30 million in cash at closing and may pay up to $70 million in contingent milestone payments tied to TYRVAYA’s net sales, for potential total consideration of up to $100 million. The closing payment was funded with cash on hand. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is the first and only FDA-approved nasal spray for DED. Unlike topical ophthalmic therapies, TYRVAYA is administered through the nose and is thought to activate the trigeminal parasympathetic pathway to stimulate basal tear production. TYRVAYA is approved in the U.S., China, and Taiwan, with marketing applications pending in additional markets. The addition of TYRVAYA meaningfully expands Harrow’s position in the large and growing U.S. dry eye market and...",
    "product": "TYRVAYA",
    "summary": "Viatris Inc. has sold the worldwide rights (excluding Japan) for its TYRVAYA® nasal spray to Harrow for $30 million in cash, with potential for up to $70 million in additional milestone payments.",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/8e0382bf-e00a-4591-87aa-4e90001aabea",
    "confidence": 1,
    "product_data": {
      "name": "TYRVAYA",
      "full_text": "TYRVAYA ® (varenicline solution) nasal spray 0.03 mg",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-05T11:00:00Z",
    "effective_date": "2026-10-05",
    "article_sentence": "Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced acquisition of TYRVAYA ® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company.",
    "amount_normalized": 30000000,
    "related_company_name": "Harrow",
    "related_company_domain": "harrow.com"
  }
}

curl https://signals.autobound.ai/v1/signals/f90be767-e414-0c98-5bd6-fbe9a0aec51a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"viatris.com","limit":20}'